



COMPANY DESCRIPTION

FORMYCON is a leading independent pure play developer of biosimilars for global marketing. The team of FORMYCON has extensive experience in complex biological molecules. FORMYCON's specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the US. FORMYCON currently has four biosimilars under development, each expected to target a multi billion dollar originator market. Two of them have been licensed out to Bioeq IP AG and to Santo Holding GmbH. Another biosimilar will be further developed in a joint venture with Aristo Pharma GmbH.

Biosimilars are follow-on versions of biopharmaceuticals, for which patent protection/exclusivity has expired. These products represent a rapidly growing new field of pharmaceutical biotechnology and clinical research. While the global market for biosimilars is currently some USD 3.0 billion, industry experts expect this figure to grow tenfold by 2025. In contrast to traditional generic drugs, the development and production of biosimilars is highly complex and requires specialized expertise.

PIPELINE	Reference Product Active Ingredient Disease Area	Indications	Partner	Preclinical Phase	Clinical Phase I	Clinical Phase III
FYB 201	Lucentis® ranibizumab ophthalmology	wAMD, DME, RVO, mCNV, DR*	Bioeq IP AG	✓	✓	✓
FYB 202	Stelara® ustekinumab immunology	Pso, PsA, CD	Aristo Pharma GmbH	Start Q2/2019		
FYB 203	Eylea® afibercept ophthalmology	wAMD, DME, RVO, DR*, mCNV**	Santo Holding GmbH			
FYB 205		🔒				

* FDA approval only ** EMA approval only

STRATEGY AND GOALS

FORMYCON is specifically concentrating on the "third wave" of biosimilars, namely follow-on products for blockbuster biopharmaceuticals with patent expiries beginning in the year 2020. Because FORMYCON has focused its efforts on this generation of biosimilars at a timely stage, the company has been able to carve out for itself a unique and leading position in this market space. It's the strategic goal to further strengthen that status and, as a leading independent developer of biosimilars, to assume a key role in this global market. In pursuing this ambition, FORMYCON continuously positions itself as a desirable, sought-after partner for major pharmaceutical and generic drug companies.

FORMYCON strives to cover the entire value creation chain, from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval, putting the company in a position to offer a complete, end-to-end development concept to its partners.

FACTS

Founded	2007
Headquarters	Planegg/Munich
Employees	~ 95
Management	Dr. Carsten Brockmeyer (CEO) Dr. Nicolas Combé (CFO) Dr. Stefan Glombitza (COO)

KEY FINANCIALS (in € million)

	2015	2016	2017	2018e*
Revenue	16.9	19.5	29.0	40.5
Operating Income	0.5	-4.1	-1.5	7.7
Equity Capital Ratio (in %)	91.5	82.9	82.9	N/A
Liquid Resources	23.1	19.2	26.0	20.3

*Estimated by First Berlin

HIGHLIGHTS 2017/2018

NOV 2018	Formycon Releases Updates on Development Programs and Milestones
NOV 2018	Reporting of Nine-Month Figures for 2018
SEP 2018	Formycon Reports Financial and Operating Results for the First Half Year of 2018
AUG 2018	Development and production expert Thomas Siklosi appointed to Advisory Board
MAY 2018	Formycon with successful 2017 Financial Year
MAY 2018	Biosimilar Candidate FYB201 shows efficacy comparable to the reference product in phase III
APR 2018	Formycon ranks 7th in the Financial Times List of Europe's 1000 Strongest-Growing Companies
DEC 2017	FYB202 Joint venture with Aristo Pharma
NOV 2017	Focus: Formycon growth champion again
JUL 2017	Formycon signs term sheet for development of FYB202 and executes capital increase
MAY 2017	Announcement: FYB202 is a biosimilar candidate for Stelara® (ustekinumab)
MAR 2017	Change to new stock exchange segment "Scale"

MARKET DATA

Stock Symbol	DE000A1EWVY8
Market Segment	Börse Frankfurt, Segment „Scale“
Market Capitalization	~ € 285 million
Shares Outstanding	9,422,603
Shareholders	15 % Institutional Investors 35 % Family Offices 15 % Founders and Management 35 % Free Float

CONTACT: Sabrina Müller Corporate Communications & Investor Relations Tel.: + 49 89 86 46 67 149 E-Mail: sabrina.mueller@formycon.com

This document may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.